To date, crizotinib, a small molecule ATP analogue inhibitor of ALK, ROS1, and MET, is approved by FDA, EMA, and AIFA for the treatment of patients with ALK or ROS1-positive NSCLC [42,47]. This evidence concerns the gene ALK and non-small cell lung carcinoma.